Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25574265 | 0.96 | GPR142 (0.57) | GPR142TRPV1HTR2AHTR2CNAMPT | |
| SCHEMBL25574260 | 0.92 | MAPT (0.55) | GPR142TRPV1HTR2AHTR2CNAMPT | |
| SCHEMBL25574262 | 0.88 | GPR142 (0.57) | GPR142TRPV1HTR2AHTR2CNAMPT | |
| SCHEMBL25209775 | 0.87 | GPR142 (0.70) | GPR142TRPV1NAMPTNPC1CASP3 | |
| SCHEMBL25208411 | 0.86 | KMT2A (0.65) | TRPV1NAMPTNPC1CASP3RAB9A | |
| SCHEMBL25574345 | 0.86 | TRPV1 (0.55) | GPR142TRPV1NPC1CASP3RAB9A | |
| SCHEMBL25237483 | 0.85 | TRPV1 (0.54) | GPR142TRPV1NPC1CASP3RAB9A | |
| SCHEMBL25574314 | 0.84 | MEN1 (0.56) | GPR142TRPV1NPC1CASP3RAB9A | |
| SCHEMBL25574256 | 0.84 | TRPV1 (0.55) | GPR142TRPV1HTR2AHTR2CCCR2 | |
| SCHEMBL25227563 | 0.84 | TRPV1 (0.53) | GPR142TRPV1NPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116783190-A | N- (phenylaminocarbonyl) tetrahydroisoquinolines and related compounds as modulators of GPR65 | 帕蒂奥斯治疗有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230174530-A1 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-06-08 | — | — | US | disclosed |
| US-20230174530-A1 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-06-08 | — | — | US | disclosed |
| US-20230174530-A1 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-06-08 | — | — | US | disclosed |
| EP-4161643-A1 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174530-A1 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | GPR3, GPR65, GPR52 | GPR142 40/4885TRPV1 206/4885HTR2A 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.